Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum

Veterinary Parasitology

Volumn 75, Issue 1, 1998, Pages 33-40

  Valladares, Josep Enric ^a   Riera, Cristina ^b   Alberola, Jordi ^a   Gállego, Montserrat ^b   Portús, Montserrat ^b   Cristòfol, Carles ^a   Franquelo, Carme ^a   Arboix, Margarita ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Control methods Protozoa; Dog; Leishmania infantum; Meglumine antimoniate; Pharmacokinetics

Indexed keywords

MEGLUMINE ANTIMONATE; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; EXPERIMENTAL INFECTION; LEISHMANIA INFANTUM; LEISHMANIASIS; MALE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIPROTOZOAL AGENTS; DOG DISEASES; DOGS; DRUG ADMINISTRATION SCHEDULE; INJECTIONS, SUBCUTANEOUS; LEISHMANIA INFANTUM; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; METABOLIC CLEARANCE RATE; ORGANOMETALLIC COMPOUNDS;

ANIMALIA; CANIS FAMILIARIS; LEISHMANIA INFANTUM; PROTOZOA;

EID: 0032519660     PISSN: 03044017     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-4017(97)00193-3     Document Type: Article

References (19)

1. Al-Jaser M., El-Yazigi A., Croft S.L. Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis. Pharm. Res. 12:1995;113-116.
2. Alvar J. Leishmaniasis and AIDS co-infection: the Spanish example. Parasitol. Today. 10:1994;160-163.
3. Bettini S., Gradoni L. Canine leishmaniasis in the Mediterranean area and its implications for human leishmaniasis. Insect. Sci. Appl. 7:1986;241-245.
4. Chulay J.D., Fleckenstein L., Smith D.H. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans. R. Soc. Trop. Med. Hyg. 82:1988;69-72.
5. Collins M., Carter K.C., Baillie A.J. Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Ann. Trop. Med. Parasitol. 86:1992;35-40.
6. Costantini S., Giordani R., Rizzica M., Benedetti F. Applicability of anodic-striping voltammetry and graphite furnace atomic-absorption spectrometry to the determination of antimony in biological matrices: a comparative study. Analyst. 110:1985;1355-1359.
7. Ferrer L., Aisa M.J., Roura X., Portús M. Serological diagnosis and treatment of canine leishmaniasis. Vet. Rec. 136:1995;514-516.
8. Fisa R., Gállego M., Riera C., Aisa M.J., Valls D., Serra T., de Colmenares M., Castillejo S., Portús M. Serologic diagnosis of canine leishmaniasis by dot-ELISA. J. Vet. Diagn. Invest. 5:1997;50-57.
9. Gebre-Hiwott A., Tadesse G., Croft S.L., Frommel D. An in vitro model for screening anti-leishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop. 51:1992;237-245.
10. Grögl M., Odoula A.M., Cordero L.D., Kyle D.E. Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure. Exp. Parasitol. 69:1989;78-90.
11. Grögl M., Thomason T., Franke E.D. Drug resistance in leishmaniasis: its implications in systemic chemotherapy of cutaneous and mucocutaneous disease. Am. J. Trop. Med. Hyg. 47:1992;117-126.
12. Mancianti F., Gramicia M., Gradoni L., Pieri S. Studies on canine leishmaniasis control: 1. Evolution of infection of different clinical forms of canine leishmaniasis following antimonial treatment. Trans. R. Soc. Trop. Med. Hyg. 82:1988;566-567.
13. Metzler, C.M., Weiner, D.L., 1992. PCNONLIN Users guide. Statistical Consultants, Lexington, KY.
14. Neal R.A., Matthews P.J. In vitro anti-leishmanial properties of pentavalent antimony compounds. Trans. R. Soc. Trop. Med. Hyg. 76:1982;284.
15. Slappendel, R.J., Greene, C.E., 1990. Leishmaniasis. In: Greene, C.E. (Ed.), Infectious Diseases of the Dog and Cat. Saunders, Philadelphia, PA, pp. 769-777.
16. Tassi P., Ormas P., Madonna M., Carli S., Belloli C., De Natale G., Marcotrigiano G.O. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog. Res. Vet. Sci. 56:1994;144-150.
17. Valladares J.E., Alberola J., Esteban M., Arboix M. Disposition of antimony after administration of N-methylglucamine antimoniate to dogs. Vet. Rec. 138:1996;181-183.
18. WHO, 1990. Control of the Leishmaniasis. World Health Organization, Geneva, Technical Report Series, No. 793.
19. Yamaoka K., Nakagawa T., Uno T. Application of Akaike's Information Criterion (AIC) in the evaluation of pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:1978;164-175.